• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续性扁桃体炎作为类风湿关节炎中甲氨蝶呤诱导的EB病毒阳性淋巴增殖性疾病的非典型初始表现:一例报告及文献复习

Protracted Tonsillitis as an Atypical Initial Manifestation of Methotrexate-Induced EBV-Positive Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report and Literature Review.

作者信息

Lin Ting-Shen, Tsao Tang-Yi, Chen Shih-Wei, Ko Min-Cheng, Tsai Stella Chin-Shaw

机构信息

Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung 435, Taiwan.

Department of Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung 435, Taiwan.

出版信息

Diagnostics (Basel). 2025 Jun 14;15(12):1517. doi: 10.3390/diagnostics15121517.

DOI:10.3390/diagnostics15121517
PMID:40564838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12191951/
Abstract

Methotrexate is widely used as a disease-modifying antirheumatic drug for rheumatoid arthritis (RA), yet prolonged immunosuppression may lead to rare complications, including Epstein-Barr virus (EBV)-positive lymphoproliferative disorders (LPDs). We present the case of a 70-year-old woman with RA on chronic immunosuppressive therapy who developed symptoms resembling recurrent tonsillitis. CT imaging revealed bilateral necrotic palatine tonsils and extensive necrotic lymphadenopathy involving the cervical, mediastinal, and axillary regions. Bilateral tonsillectomy was performed due to concerns about malignancy or infection, and histopathology confirmed a polymorphic EBV-positive LPD with Hodgkin-like features, consistent with iatrogenic immunodeficiency-associated LPD. Methotrexate was subsequently discontinued, and the patient was managed conservatively without systemic chemotherapy. Clinical recovery was observed during follow-up. This case highlights the importance of considering methotrexate-associated LPDs in the differential diagnosis of atypical tonsillar infections in immunosuppressed patients, particularly when necrotic features or systemic lymphadenopathy are present. The pathogenesis may involve EBV reactivation under impaired immune surveillance due to methotrexate, leading to abnormal B-cell proliferation and clonal expansion. This case is contextualized through a comparative analysis of published reports, highlighting clinical features and treatment responses of methotrexate-associated EBV-positive LPDs in the form of a focused literature review.

摘要

甲氨蝶呤作为一种改善病情的抗风湿药物,被广泛用于治疗类风湿关节炎(RA),然而长期免疫抑制可能导致罕见的并发症,包括 Epstein-Barr 病毒(EBV)阳性淋巴增殖性疾病(LPDs)。我们报告了一例 70 岁患有 RA 的女性患者,她接受慢性免疫抑制治疗,出现了类似复发性扁桃体炎的症状。CT 成像显示双侧坏死性腭扁桃体以及累及颈部、纵隔和腋窝区域的广泛坏死性淋巴结病。由于担心恶性肿瘤或感染,进行了双侧扁桃体切除术,组织病理学证实为具有霍奇金样特征的多形性 EBV 阳性 LPD,符合医源性免疫缺陷相关的 LPD。随后停用了甲氨蝶呤,患者接受保守治疗,未进行全身化疗。随访期间观察到临床恢复。该病例强调了在免疫抑制患者非典型扁桃体感染的鉴别诊断中考虑甲氨蝶呤相关 LPD 的重要性,特别是当出现坏死特征或全身淋巴结病时。其发病机制可能涉及由于甲氨蝶呤导致免疫监视受损下的 EBV 重新激活,从而导致异常 B 细胞增殖和克隆性扩增。通过对已发表报告的比较分析将该病例进行背景化,以聚焦文献综述的形式突出了甲氨蝶呤相关 EBV 阳性 LPD 的临床特征和治疗反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/fdf0063d202d/diagnostics-15-01517-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/e01c6bf60d1d/diagnostics-15-01517-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/f3f073d8ef08/diagnostics-15-01517-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/fdf0063d202d/diagnostics-15-01517-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/e01c6bf60d1d/diagnostics-15-01517-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/f3f073d8ef08/diagnostics-15-01517-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba2/12191951/fdf0063d202d/diagnostics-15-01517-g003.jpg

相似文献

1
Protracted Tonsillitis as an Atypical Initial Manifestation of Methotrexate-Induced EBV-Positive Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report and Literature Review.持续性扁桃体炎作为类风湿关节炎中甲氨蝶呤诱导的EB病毒阳性淋巴增殖性疾病的非典型初始表现:一例报告及文献复习
Diagnostics (Basel). 2025 Jun 14;15(12):1517. doi: 10.3390/diagnostics15121517.
2
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
3
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
4
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎:系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
5
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
6
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).生物制剂或托法替布单药治疗传统抗风湿药物(DMARD)治疗失败的类风湿关节炎患者:一项Cochrane系统评价和网状Meta分析(NMA)
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD012437. doi: 10.1002/14651858.CD012437.
7
Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.美国医疗保健研究与质量局(AHRQ)对用于青少年特发性关节炎患儿的改善病情抗风湿药的比较效果评价总结。
J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl B):1-16. doi: 10.18553/jmcp.2012.18.S1-B.1.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.阿那白滞素治疗成人类风湿关节炎的临床疗效与成本效益:一项系统评价与经济分析
Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180.
10
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.

本文引用的文献

1
Enhancing the diagnostic accuracy of core needle biopsy in patients with lymphoproliferative disorders by an optimized protocol.通过优化方案提高针吸活检对淋巴增生性疾病患者的诊断准确性。
Radiol Med. 2025 Apr 1. doi: 10.1007/s11547-025-01976-2.
2
EBV + B cell-derived exosomes promote EBV-associated T/NK-cell lymphoproliferative disease immune evasion by STAT3/IL-10/PD-L1 pathway.EBV阳性B细胞来源的外泌体通过STAT3/IL-10/PD-L1途径促进EBV相关的T/NK细胞淋巴增殖性疾病的免疫逃逸。
Immunol Res. 2024 Dec;72(6):1327-1336. doi: 10.1007/s12026-024-09531-3. Epub 2024 Aug 20.
3
Epstein-Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases.
爱泼斯坦-巴尔病毒:它们的免疫逃逸策略及其对自身免疫性疾病的影响。
Int J Mol Sci. 2024 Jul 26;25(15):8160. doi: 10.3390/ijms25158160.
4
Treatment of Epstein-Barr Virus infection in immunocompromised patients.免疫功能低下患者的 EBV 感染治疗。
Biochem Pharmacol. 2024 Jul;225:116270. doi: 10.1016/j.bcp.2024.116270. Epub 2024 May 10.
5
The first case of methotrexate-associated lymphoproliferative disorder in the sacrum: a case report.首例骶骨部位与甲氨蝶呤相关的淋巴增殖性疾病:病例报告
BJR Case Rep. 2024 Jan 23;10(1):uaae002. doi: 10.1093/bjrcr/uaae002. eCollection 2024 Jan.
6
Immunity and Immune Evasion Mechanisms of Epstein-Barr Virus.EB 病毒的免疫与免疫逃逸机制。
Viral Immunol. 2023 Jun;36(5):303-317. doi: 10.1089/vim.2022.0200. Epub 2023 Jun 6.
7
Tonsillitis and Tonsilloliths: Diagnosis and Management.扁桃体炎和扁桃体结石:诊断与管理。
Am Fam Physician. 2023 Jan;107(1):35-41.
8
EBV-associated diseases: Current therapeutics and emerging technologies.EBV 相关疾病:当前的治疗方法和新兴技术。
Front Immunol. 2022 Oct 27;13:1059133. doi: 10.3389/fimmu.2022.1059133. eCollection 2022.
9
Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features.原发性皮肤甲氨蝶呤相关的 B 细胞淋巴增生性疾病,除外 EBV 阳性黏膜溃疡性疾病:临床、病理和免疫表型特征。
Pathology. 2021 Aug;53(5):595-601. doi: 10.1016/j.pathol.2020.10.019. Epub 2021 Feb 19.
10
Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions.甲氨蝶呤相关性淋巴组织增生性疾病的临床病理评估,特别关注 EBV 阳性黏膜皮肤损害。
J Clin Exp Hematop. 2020 Dec 15;60(4):159-168. doi: 10.3960/jslrt.20041. Epub 2020 Nov 4.